Keywords: genaera, shares, rise, following, positive, findings, squalamine

Genaera shares rise following positive findings for squalamine as AMD therapy

Article | 11 August 2003

Print This

USA-based Genaera has released successful preliminary results from a Phase I/II trial evaluating its anti-angiogenic drug, squalamine, as a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in